Risk of delayed human papillomavirus vaccination in inner-city adolescent women

Nicolas F. Schlecht, Angela Diaz, Shankar Viswanathan, Arnold H. Szporn, Maoxin Wu, Anne Nucci-Sack, Ken Peake, Howard Strickler, Robert D. Burk

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations. Methods. We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses. Results. Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95% confidence interval [CI], .1-.4) and the related types HPV31 and HPV45 (0.4 [95% CI, .2-1.0] and 0.3 [95% CI, .1-.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2-.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95% CI, 1.0-8.0) and associated cytological abnormalities (HR, 4.5; 95% CI, .7-26.0) among women immunized at ?15 years of age who took ?12 months (vs <12 months) to complete the 3-dose regimen. Conclusions. Among adolescents immunized at ?15 years of age, a longer time to complete the 3-dose schedule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased incidence of associated cervical cytological abnormalities.

Original languageEnglish (US)
Pages (from-to)1952-1960
Number of pages9
JournalJournal of Infectious Diseases
Volume214
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Vaccination
Confidence Intervals
Vaccines
Papillomavirus Vaccines
Incidence
Infection
Longitudinal Studies
Appointments and Schedules
Polymerase Chain Reaction
Population

Keywords

  • Adolescent medicine
  • Cervical neoplasia
  • Human papillomavirus
  • Vaccination
  • Women's health

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Risk of delayed human papillomavirus vaccination in inner-city adolescent women. / Schlecht, Nicolas F.; Diaz, Angela; Viswanathan, Shankar; Szporn, Arnold H.; Wu, Maoxin; Nucci-Sack, Anne; Peake, Ken; Strickler, Howard; Burk, Robert D.

In: Journal of Infectious Diseases, Vol. 214, No. 12, 01.12.2016, p. 1952-1960.

Research output: Contribution to journalArticle

Schlecht, Nicolas F. ; Diaz, Angela ; Viswanathan, Shankar ; Szporn, Arnold H. ; Wu, Maoxin ; Nucci-Sack, Anne ; Peake, Ken ; Strickler, Howard ; Burk, Robert D. / Risk of delayed human papillomavirus vaccination in inner-city adolescent women. In: Journal of Infectious Diseases. 2016 ; Vol. 214, No. 12. pp. 1952-1960.
@article{6bb18deb6182494c96bfa1f7d5ed89c7,
title = "Risk of delayed human papillomavirus vaccination in inner-city adolescent women",
abstract = "Background. Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations. Methods. We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses. Results. Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95{\%} confidence interval [CI], .1-.4) and the related types HPV31 and HPV45 (0.4 [95{\%} CI, .2-1.0] and 0.3 [95{\%} CI, .1-.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95{\%} CI, .2-.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95{\%} CI, 1.0-8.0) and associated cytological abnormalities (HR, 4.5; 95{\%} CI, .7-26.0) among women immunized at ?15 years of age who took ?12 months (vs <12 months) to complete the 3-dose regimen. Conclusions. Among adolescents immunized at ?15 years of age, a longer time to complete the 3-dose schedule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased incidence of associated cervical cytological abnormalities.",
keywords = "Adolescent medicine, Cervical neoplasia, Human papillomavirus, Vaccination, Women's health",
author = "Schlecht, {Nicolas F.} and Angela Diaz and Shankar Viswanathan and Szporn, {Arnold H.} and Maoxin Wu and Anne Nucci-Sack and Ken Peake and Howard Strickler and Burk, {Robert D.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/infdis/jiw486",
language = "English (US)",
volume = "214",
pages = "1952--1960",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Risk of delayed human papillomavirus vaccination in inner-city adolescent women

AU - Schlecht, Nicolas F.

AU - Diaz, Angela

AU - Viswanathan, Shankar

AU - Szporn, Arnold H.

AU - Wu, Maoxin

AU - Nucci-Sack, Anne

AU - Peake, Ken

AU - Strickler, Howard

AU - Burk, Robert D.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background. Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations. Methods. We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses. Results. Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95% confidence interval [CI], .1-.4) and the related types HPV31 and HPV45 (0.4 [95% CI, .2-1.0] and 0.3 [95% CI, .1-.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2-.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95% CI, 1.0-8.0) and associated cytological abnormalities (HR, 4.5; 95% CI, .7-26.0) among women immunized at ?15 years of age who took ?12 months (vs <12 months) to complete the 3-dose regimen. Conclusions. Among adolescents immunized at ?15 years of age, a longer time to complete the 3-dose schedule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased incidence of associated cervical cytological abnormalities.

AB - Background. Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations. Methods. We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses. Results. Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95% confidence interval [CI], .1-.4) and the related types HPV31 and HPV45 (0.4 [95% CI, .2-1.0] and 0.3 [95% CI, .1-.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2-.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95% CI, 1.0-8.0) and associated cytological abnormalities (HR, 4.5; 95% CI, .7-26.0) among women immunized at ?15 years of age who took ?12 months (vs <12 months) to complete the 3-dose regimen. Conclusions. Among adolescents immunized at ?15 years of age, a longer time to complete the 3-dose schedule was associated with an increased risk of anogenital HPV6/11/16/18 infection and an increased incidence of associated cervical cytological abnormalities.

KW - Adolescent medicine

KW - Cervical neoplasia

KW - Human papillomavirus

KW - Vaccination

KW - Women's health

UR - http://www.scopus.com/inward/record.url?scp=85016053210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016053210&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw486

DO - 10.1093/infdis/jiw486

M3 - Article

C2 - 27738056

AN - SCOPUS:85016053210

VL - 214

SP - 1952

EP - 1960

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -